Evidence map›Paper›PMID 24877793›Full record

ArticleAccounts of chemical research2014

Synthetic zinc finger proteins: the advent of targeted gene regulation and genome modification technologies.

Charles A Gersbach, Thomas Gaj, Carlos F Barbas

Abstract read
In one paragraph

Article in Accounts of chemical research, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 72 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
72citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

72 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. The past, present, and future of artificial zinc finger proteins: design strategies and chemical and biological applications.Journal of biological inorganic chemistry : JBIC : a publication of the Society of Biological Inorganic Chemistry · 2023
    Pooled it
  2. Article
  3. Advances and clinical potential of epigenome editing.Cellular and molecular life sciences : CMLS · 2026
    Review
  4. Epigenome editing based treatment: Progresses and challenges.Molecular therapy : the journal of the American Society of Gene Therapy · 2026
    Review
  5. Review
  6. Article
  7. Human Synthetic Biology and Programmable Gene Regulation Control.Annual review of genomics and human genetics · 2025
    Review
  8. Current trends in gene therapy to treat inherited disorders of the brain.Molecular therapy : the journal of the American Society of Gene Therapy · 2025
    Review
  9. Review
  10. Blood Leukocyte DNA Methylation Markers of Periodontal Disease and Risk of Lung Cancer in a Case-Control Study Nested in the CLUE II Cohort.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2024
    Article
  11. Review
  12. Artificial viruses: A nanotechnology based approach.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2024
    Review
  13. Synthetic Gene Circuits for Regulation of Next-Generation Cell-Based Therapeutics.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024
    Review
  14. Article
  15. Review
  16. Article
  17. Deletions of DNA in cancer and their possible uses for therapy.BioEssays : news and reviews in molecular, cellular and developmental biology · 2023
    Article
  18. Trends and prospects in mitochondrial genome editing.Experimental & molecular medicine · 2023
    Review
  19. Article
  20. Article

12 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Charles A GersbachDepartment of Biomedical Engineering, Duke University , Durham, North Carolina 27708, United States.
Thomas Gaj
Carlos F Barbas

Funding

Engineering Targeted Epigenetic Modifiers for Precise Control of Gene RegulationR01DA036865 · NIDA · DUKE UNIVERSITY · PI CRAWFORD, GREGORY E, GERSBACH, CHARLES A. · 2013 to 2017
$2.6M
Engineering Morphogenetic Factors for Enhanced Genetic ReprogrammingDP2OD008586 · OD · DUKE UNIVERSITY · PI GERSBACH, CHARLES A. · 2011 to 2011
$2.4M
Chemically Programmed ImmunityDP1CA174426 · NCI · SCRIPPS RESEARCH INSTITUTE, THE · PI DAWSON, PHILIP E · 2012 to 2014
$2.3M
Predoctoral Training Program in Molecular EvolutionT32GM080209 · NIGMS · SCRIPPS RESEARCH INSTITUTE, THE · PI FINN, M.G. · 2009 to 2011
$461k
NCI NIH HHS DP1 CA174426NCI NIH HHS DP1CA174426NIDA NIH HHS R01 DA036865NIDA NIH HHS R01DA036865NIGMS NIH HHS T32 GM080209NIGMS NIH HHS T32GM080209NIH HHS DP2 OD008586NIH HHS DP2OD008586
6 · The paper itself

Abstract

The understanding of gene regulation and the structure and function of the human genome increased dramatically at the end of the 20th century. Yet the technologies for manipulating the genome have been slower to develop. For instance, the field of gene therapy has been focused on correcting genetic diseases and augmenting tissue repair for more than 40 years. However, with the exception of a few very low efficiency approaches, conventional genetic engineering methods have only been able to add auxiliary genes to cells. This has been a substantial obstacle to the clinical success of gene therapies and has also led to severe unintended consequences in several cases. Therefore, technologies that facilitate the precise modification of cellular genomes have diverse and significant implications in many facets of research and are essential for translating the products of the Genomic Revolution into tangible benefits for medicine and biotechnology. To address this need, in the 1990s, we embarked on a mission to develop technologies for engineering protein-DNA interactions with the aim of creating custom tools capable of targeting any DNA sequence. Our goal has been to allow researchers to reach into genomes to specifically regulate, knock out, or replace any gene. To realize these goals, we initially focused on understanding and manipulating zinc finger proteins. In particular, we sought to create a simple and straightforward method that enables unspecialized laboratories to engineer custom DNA-modifying proteins using only defined modular components, a web-based utility, and standard recombinant DNA technology. Two significant challenges we faced were (i) the development of zinc finger domains that target sequences not recognized by naturally occurring zinc finger proteins and (ii) determining how individual zinc finger domains could be tethered together as polydactyl proteins to recognize unique locations within complex genomes. We and others have since used this modular assembly method to engineer artificial proteins and enzymes that activate, repress, or create defined changes to user-specified genes in human cells, plants, and other organisms. We have also engineered novel methods for externally controlling protein activity and delivery, as well as developed new strategies for the directed evolution of protein and enzyme function. This Account summarizes our work in these areas and highlights independent studies that have successfully used the modular assembly approach to create proteins with novel function. We also discuss emerging alternative methods for genomic targeting, including transcription activator-like effectors (TALEs) and CRISPR/Cas systems, and how they complement the synthetic zinc finger protein technology.

Indexed as

Genome, HumanDeoxyribonucleasesDNADNA-Binding ProteinsEarly Growth Response Protein 1Gene Expression RegulationHumansProtein Structure, TertiaryRecombinasesTranscription FactorsZinc FingersDeoxyribonucleasesDNADNA-Binding ProteinsEarly Growth Response Protein 1EGR1 protein, humanRecombinasesTranscription Factors

Identifiers

PMID24877793
PMCPMC4139171

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.